Silence Therapeutics aims at Takeda with new data in rare blood cancer

Silence Therapeutics is challenging Takeda in the treatment of polycythemia vera, a rare blood cancer. The company has announced positive mid-stage results for its gene-silencing drug, divesiran. The drug met its primary response endpoint in patients dependent on phlebotomy, a procedure to remove blood. Silence Therapeutics is now preparing to advance divesiran to Phase III trials.

The timing of this announcement is significant. Silence Therapeutics is positioning itself as a strong competitor to Takeda, which also has a drug in development for polycythemia vera. The new data from Silence Therapeutics suggests that divesiran could be a viable alternative to Takeda's treatment. This development is particularly noteworthy because polycythemia vera is a challenging condition to treat, and effective therapies are limited.

However, the path forward is not without obstacles. Silence Therapeutics will need to demonstrate the long-term safety and efficacy of divesiran in larger, more diverse patient populations. Additionally, regulatory approval is not guaranteed, and the competitive landscape could shift based on future developments from Takeda and other companies in the field.